,Chapter 01: Information Sources, Regulatory Agencies, Drug Legislation, and Prescription
b b b b b b b b b
Writing
b
Haveles: Applied Pharmacology forthe Dental Hygienist,9th Edition
b b b b b b b b
MULTIPLECHOICE
1. Knowledgeofpharmacologyaidsthedentalprofessionalin
a. obtainingapatient’shealth history. B
b. administeringdrugsintheoffice.
c. handlingemergencysituations.
d. selectionofa nonprescription medication. b B
e. Alloftheabove.
ANS: E x
All oft hechoicesaretrue.Becausemanyofourpatientsarebeingtreatedwithdrugs,knowledgeof
B B x B B
pharmacologyhelpsinunderstandingandinterpretingpatients’responsestohealthhistoryquestions.
x
Knowledgeofthetherapeuticandadverseeffectsofmedicationsobviouslyhelpsint heirproper
x B x
administrationint heoffice.Emergencysituationsmaybecausedbydrugsortreatedbydrugs;thus,knowledge
x B x B B B
ofpharmacologyisofgreathelp,especiallybecausear apidr esponseissometimesrequired.Aclear
x B B x B x B
understandingoftheconceptsofdrugaction,drughandlingbythebody,anddrugi nteractionswillallowthe
x B B B B x
dentalpractitionertomakeproperjudgmentsandgrasptheconceptsrelevantt onewdrugtherapiesonthe
x B B x
market.
x
DIF: Application
REF: RoleoftheDentalHygienist(
x B
xMedication/HealthHistory),RoleoftheDentalHygienist(Medication
Administration),RoleoftheDentalHygienist(EmergencySituations),RoleoftheDentalHygienist
x B B
(NonprescriptionMedication)|pp.2-3
x OBJ: 1B x
TOP: NBDHE,6.0.Pharmacology
x
2. Whichofthefollowingstatementsist rueregardingplanningappointments? B x
a. Whetherornotpatientsaretaking medicationforsystemicdiseasesi s ofl ittle
B b B x B B x
consequenceinthedentaloffice.
x
b. Asthmaticpatientsshouldhavedentalappointmentsinthemorning. B
c. Diabeticpatientsusuallyhavefewerproblemswith amorningappointment x b
comparedwithafternoonappointments.
x B B
d. BothBandCaretrue. B B
ANS: D x
Asthmaticpatientswhoexperiencedentalanxietyshouldscheduletheirappointmentswhentheyarenot B
rushedorunderpressureearlyint hemorning.Diabeticpatientsusuallyhaverelativelyfewerproblems
x B x
withamorningappointment.Patientstakingmedicationforsystemicdiseasesmayrequirespecialhandling
x
inthedentaloffice.
x B
DIF: Comprehension
REF: RoleoftheDentalHygienist(
x B B
xAppointmentScheduling)|p.3 OBJ: 1 B x x TOP:
xNBDHE,6.0.Pharmacology
,3. Nutritionalorherbalsupplements
a. carrytheU.S.FoodandDrugAdministration(FDA)approvalfordiseasestates. B B B
b. arenotdrugs.
c. cancauseadverseeffects.
B
d. willnotinteractwithotherdrugst hepatientmaybetaking. B B x B x
ANS: C x
Nutritionalorherbalsupplementsarequitecapableofcausingadverseeffects. Themajorityof nutritional or x x x
herbalsupplements do notcarry FDAapprovalfortreatingdiseasestates. Thesesupplementsaredrugsand can
x x x x x x
causeadverseeffects andi nteractwithdifferentdrugs.
x B B B x B
DIF: Comprehension
x x
REF: RoleoftheDentalHygienist(
x B
xNutritionalorHerbalSupplements)|p.3 OBJ: 1 TOP:
B B x x
xNBDHE,6.0.Pharmacology
4. Whichtypeofdrugnameusuallybeginswithal owercaseletter? B x
a. Brandname
b. Codename
c. Genericname
d. Tradename
ANS: C x
Beforeanydrugismarketed,itisgivenagenericnamethatbecomesthe“official”nameofthedrug.Each drug B
xisassignedonlyonegenericnameselectedbytheU.S.AdoptedNameCouncil,andthenameisnotcapitalized.
B B B
Thebrandnameisequivalentt othetradenameandi scapitalized.Althoughthebrandnameis
x B x B x B
technicallythenameofthecompanymarketingtheproduct,thistermisoftenusedinterchangeablywith the
x x
tradename.Thecodenameist heinitialtermusedwithinapharmaceuticalcompanytorefertoadrug whileit
x B B x B B B
isundergoinginvestigationandi softenacombinationofcapitalletters andnumbers,t helettersrepresenting
x B x B B B x
anabbreviationofthecompanyname.
x B
DIF: Comprehension REF: Drug Names|p.4 x b x
OBJ: 3
x x TOP: NBDHE,6.0.Pharmacology x
5. Adrug’sgenericnameisselectedbythe
B
a. pharmaceuticalcompanymanufacturing it. x
b. FoodandDrugAdministration(FDA). B B B
c. U.S.AdoptedNameCouncil. B
d. FederalPatentOffice. B
ANS: C x
Eachdrugisassignedonlyonegenericname(e.g.,ibuprofen).ItisselectedbytheU.S.AdoptedNameCouncil.
B B B B B
ThegenericnameisnotselectedbytheFDAortheFederalPatentOffice.Thepharmaceutical
x B B
companymanufacturingthedrugclearlyhasaninfluenceonthegenericnamegivenitsdrug,butthefinaldecision
x
xisnotthecompany’s.
DIF: Recall REF: DrugNames|p.4 x OBJ:
3TOP: NBDHE,6.0.Pharmacology
x x
6. Whichofthefollowingistrueconcerninggenericandtradenamesofdrugs? B
a. Adrugmayonlyhaveonegenericnameandonetradename.
, b. Adrugmayonlyhaveonegenericname,buti tmayhaveseveraltradenames. B x x B B
c. Adrugmayhaveseveralgenericnames,butitmayonlyhaveonetradename.
d. Adrugmayhaveseveralgenericnamesandseveraltradenames. B B
ANS: B x
Eachdrughasonlyonegenericnamebutmayhaveseveraltradenames.Foreachdrug,thereisonlyonegeneric B B
name.Iti snotcapitalized,andi tbecomesthe“official”nameofthedrug.Thepharmaceuticalcompany
x B x B B x
discoveringt hedruggivesthedrugatradename.ThetradenameisprotectedbytheFederalPatentLawfor20
x B x B B
yearsfromtheearliestclaimedfilingdate,pluspatenttermextensions.Althoughthe
x B
xbrandnameistechnicallythenameofthecompanymarketingtheproduct,itisoftenusedinterchangeably B B
xwiththetradename.
DIF: Comprehension REF: Drug Names|p.4 x b x
OBJ: 3
x TOP: NBDHE,6.0.Pharmacology
x x
7. Twodrugsthatarefoundt obechemicallyequivalent,butnotbiologicallyequivalentor
B x x
x therapeuticallyequivalentaresaidtodifferin B
a. potency.
b. efficacy.
c. bioavailability.
d. therapeuticindex.
ANS: C x
Apreparationcanbechemicallyequivalentyetnotbiologicallyortherapeuticallyequivalent.These
B B B
productsaresaidtodifferintheirbioavailability.Thepotencyofadrugisafunctionoftheamountofdrug
x B
xrequiredt B
oproduceaneffect.Theefficacyisthemaximumintensityofeffectorresponsethatcanbeproduced
x B B B
byadrug.Thetherapeuticindexistheratioofthelethaldosefor50%oftheexperimentalanimalsdividedbythe
x B
effectivedosefor50%oftheexperimentalanimals.Ifthevalueoft
x B B
hetherapeuticindexissmall,toxicityismore likely.
x B x
DIF: Recall REF: DrugNames (Drug Substitution)|p.5
x x b
OBJ: 4
x x TOP: NBDHE,6.0.Pharmacology
x
8. Howmanyyearsmustpassafteradrugpatentexpiresbeforeotherdrugcompaniescanmarketthe same
x x x x x x
compoundasagenericdrug?
x
a. 20years
b. 17years
c. 7years
d. 0years
ANS: D x
Onceadrugpatentexpires,competingcompaniesmayimmediatelymarketthesamecompoundingeneric
B B B
form.Thepharmaceuticalcompanydiscoveringt hedruggivesthedrugat radename.Thetrade
x B x B B B x
nameisprotectedbytheFederalPatentLawfor20yearsfromtheearliestclaimedfilingdate,plusthepatent
x
termextensions.
x
DIF: Application REF: DrugNames (Drug Substitution)|
x x b B
p.5 OBJ: 4
x x x TOP: NBDHE,6.0.Pharmacology
x
b b b b b b b b b
Writing
b
Haveles: Applied Pharmacology forthe Dental Hygienist,9th Edition
b b b b b b b b
MULTIPLECHOICE
1. Knowledgeofpharmacologyaidsthedentalprofessionalin
a. obtainingapatient’shealth history. B
b. administeringdrugsintheoffice.
c. handlingemergencysituations.
d. selectionofa nonprescription medication. b B
e. Alloftheabove.
ANS: E x
All oft hechoicesaretrue.Becausemanyofourpatientsarebeingtreatedwithdrugs,knowledgeof
B B x B B
pharmacologyhelpsinunderstandingandinterpretingpatients’responsestohealthhistoryquestions.
x
Knowledgeofthetherapeuticandadverseeffectsofmedicationsobviouslyhelpsint heirproper
x B x
administrationint heoffice.Emergencysituationsmaybecausedbydrugsortreatedbydrugs;thus,knowledge
x B x B B B
ofpharmacologyisofgreathelp,especiallybecausear apidr esponseissometimesrequired.Aclear
x B B x B x B
understandingoftheconceptsofdrugaction,drughandlingbythebody,anddrugi nteractionswillallowthe
x B B B B x
dentalpractitionertomakeproperjudgmentsandgrasptheconceptsrelevantt onewdrugtherapiesonthe
x B B x
market.
x
DIF: Application
REF: RoleoftheDentalHygienist(
x B
xMedication/HealthHistory),RoleoftheDentalHygienist(Medication
Administration),RoleoftheDentalHygienist(EmergencySituations),RoleoftheDentalHygienist
x B B
(NonprescriptionMedication)|pp.2-3
x OBJ: 1B x
TOP: NBDHE,6.0.Pharmacology
x
2. Whichofthefollowingstatementsist rueregardingplanningappointments? B x
a. Whetherornotpatientsaretaking medicationforsystemicdiseasesi s ofl ittle
B b B x B B x
consequenceinthedentaloffice.
x
b. Asthmaticpatientsshouldhavedentalappointmentsinthemorning. B
c. Diabeticpatientsusuallyhavefewerproblemswith amorningappointment x b
comparedwithafternoonappointments.
x B B
d. BothBandCaretrue. B B
ANS: D x
Asthmaticpatientswhoexperiencedentalanxietyshouldscheduletheirappointmentswhentheyarenot B
rushedorunderpressureearlyint hemorning.Diabeticpatientsusuallyhaverelativelyfewerproblems
x B x
withamorningappointment.Patientstakingmedicationforsystemicdiseasesmayrequirespecialhandling
x
inthedentaloffice.
x B
DIF: Comprehension
REF: RoleoftheDentalHygienist(
x B B
xAppointmentScheduling)|p.3 OBJ: 1 B x x TOP:
xNBDHE,6.0.Pharmacology
,3. Nutritionalorherbalsupplements
a. carrytheU.S.FoodandDrugAdministration(FDA)approvalfordiseasestates. B B B
b. arenotdrugs.
c. cancauseadverseeffects.
B
d. willnotinteractwithotherdrugst hepatientmaybetaking. B B x B x
ANS: C x
Nutritionalorherbalsupplementsarequitecapableofcausingadverseeffects. Themajorityof nutritional or x x x
herbalsupplements do notcarry FDAapprovalfortreatingdiseasestates. Thesesupplementsaredrugsand can
x x x x x x
causeadverseeffects andi nteractwithdifferentdrugs.
x B B B x B
DIF: Comprehension
x x
REF: RoleoftheDentalHygienist(
x B
xNutritionalorHerbalSupplements)|p.3 OBJ: 1 TOP:
B B x x
xNBDHE,6.0.Pharmacology
4. Whichtypeofdrugnameusuallybeginswithal owercaseletter? B x
a. Brandname
b. Codename
c. Genericname
d. Tradename
ANS: C x
Beforeanydrugismarketed,itisgivenagenericnamethatbecomesthe“official”nameofthedrug.Each drug B
xisassignedonlyonegenericnameselectedbytheU.S.AdoptedNameCouncil,andthenameisnotcapitalized.
B B B
Thebrandnameisequivalentt othetradenameandi scapitalized.Althoughthebrandnameis
x B x B x B
technicallythenameofthecompanymarketingtheproduct,thistermisoftenusedinterchangeablywith the
x x
tradename.Thecodenameist heinitialtermusedwithinapharmaceuticalcompanytorefertoadrug whileit
x B B x B B B
isundergoinginvestigationandi softenacombinationofcapitalletters andnumbers,t helettersrepresenting
x B x B B B x
anabbreviationofthecompanyname.
x B
DIF: Comprehension REF: Drug Names|p.4 x b x
OBJ: 3
x x TOP: NBDHE,6.0.Pharmacology x
5. Adrug’sgenericnameisselectedbythe
B
a. pharmaceuticalcompanymanufacturing it. x
b. FoodandDrugAdministration(FDA). B B B
c. U.S.AdoptedNameCouncil. B
d. FederalPatentOffice. B
ANS: C x
Eachdrugisassignedonlyonegenericname(e.g.,ibuprofen).ItisselectedbytheU.S.AdoptedNameCouncil.
B B B B B
ThegenericnameisnotselectedbytheFDAortheFederalPatentOffice.Thepharmaceutical
x B B
companymanufacturingthedrugclearlyhasaninfluenceonthegenericnamegivenitsdrug,butthefinaldecision
x
xisnotthecompany’s.
DIF: Recall REF: DrugNames|p.4 x OBJ:
3TOP: NBDHE,6.0.Pharmacology
x x
6. Whichofthefollowingistrueconcerninggenericandtradenamesofdrugs? B
a. Adrugmayonlyhaveonegenericnameandonetradename.
, b. Adrugmayonlyhaveonegenericname,buti tmayhaveseveraltradenames. B x x B B
c. Adrugmayhaveseveralgenericnames,butitmayonlyhaveonetradename.
d. Adrugmayhaveseveralgenericnamesandseveraltradenames. B B
ANS: B x
Eachdrughasonlyonegenericnamebutmayhaveseveraltradenames.Foreachdrug,thereisonlyonegeneric B B
name.Iti snotcapitalized,andi tbecomesthe“official”nameofthedrug.Thepharmaceuticalcompany
x B x B B x
discoveringt hedruggivesthedrugatradename.ThetradenameisprotectedbytheFederalPatentLawfor20
x B x B B
yearsfromtheearliestclaimedfilingdate,pluspatenttermextensions.Althoughthe
x B
xbrandnameistechnicallythenameofthecompanymarketingtheproduct,itisoftenusedinterchangeably B B
xwiththetradename.
DIF: Comprehension REF: Drug Names|p.4 x b x
OBJ: 3
x TOP: NBDHE,6.0.Pharmacology
x x
7. Twodrugsthatarefoundt obechemicallyequivalent,butnotbiologicallyequivalentor
B x x
x therapeuticallyequivalentaresaidtodifferin B
a. potency.
b. efficacy.
c. bioavailability.
d. therapeuticindex.
ANS: C x
Apreparationcanbechemicallyequivalentyetnotbiologicallyortherapeuticallyequivalent.These
B B B
productsaresaidtodifferintheirbioavailability.Thepotencyofadrugisafunctionoftheamountofdrug
x B
xrequiredt B
oproduceaneffect.Theefficacyisthemaximumintensityofeffectorresponsethatcanbeproduced
x B B B
byadrug.Thetherapeuticindexistheratioofthelethaldosefor50%oftheexperimentalanimalsdividedbythe
x B
effectivedosefor50%oftheexperimentalanimals.Ifthevalueoft
x B B
hetherapeuticindexissmall,toxicityismore likely.
x B x
DIF: Recall REF: DrugNames (Drug Substitution)|p.5
x x b
OBJ: 4
x x TOP: NBDHE,6.0.Pharmacology
x
8. Howmanyyearsmustpassafteradrugpatentexpiresbeforeotherdrugcompaniescanmarketthe same
x x x x x x
compoundasagenericdrug?
x
a. 20years
b. 17years
c. 7years
d. 0years
ANS: D x
Onceadrugpatentexpires,competingcompaniesmayimmediatelymarketthesamecompoundingeneric
B B B
form.Thepharmaceuticalcompanydiscoveringt hedruggivesthedrugat radename.Thetrade
x B x B B B x
nameisprotectedbytheFederalPatentLawfor20yearsfromtheearliestclaimedfilingdate,plusthepatent
x
termextensions.
x
DIF: Application REF: DrugNames (Drug Substitution)|
x x b B
p.5 OBJ: 4
x x x TOP: NBDHE,6.0.Pharmacology
x
